Edvince AB

📍 Lund, Sweden🗓 Founded 2003👥 3 employees💰 Last funded May 2016
Biotechnology🌐 edvince.com
Website LinkedIn
Edvince is a biotech company that develops a new treatment for the management of delayed cerebral ischemic events. This treatment aims to prevent the chain of events leading to brain damage subsequent to a bleed in the brain. The company is currently in the preclinical phase and will initiate its first clinical phase I study in early 2018. Edvince is based at SmiLe Incubator in Lund and is owned by its Lars Edvinsson (founder), Krankajen Group AB, LMK Forward AB, Almi Invest Syd AB, Swedish Growth Fund and Sarah Fredriksson. The business concept is based on Professor Lars Edvinsson’s many years of research at Lund University investigating what happens in the blood vessels of the brain after a bleeding, leading to delayed cerebral ischemia. The result is the discovery of a novel first-in-class treatment, with great potential to minimize brain damage.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Edvince AB?
Edvince AB has 1 investors on record on gritt.io.
When did Edvince AB last raise funding?
The most recent investment in Edvince AB recorded on gritt.io was in May 2016.
When was Edvince AB founded?
Edvince AB was founded in 2003.
What industry is Edvince AB in?
Edvince AB operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Edvince AB based?
Edvince AB is headquartered in Lund, Sweden.